Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT02474368
Other study ID # 15-183
Secondary ID
Status Active, not recruiting
Phase Phase 1
First received
Last updated
Start date November 2015
Est. completion date June 2024

Study information

Verified date April 2024
Source Dana-Farber Cancer Institute
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This research study seeks to gain new knowledge about the addition of a carefully targeted "boost" dose of radiation as a possible treatment for recurrent or metastatic head or neck cancer. The name of the study intervention involved in this study is stereotactic body radiotherapy, which is a way of delivering radiation in a more precisely targeted way and with a higher dose than conventional radiotherapy.


Description:

This research study is a Phase I clinical trial, which tests the safety of an investigational intervention and also tries to define the appropriate dose of the investigational intervention to use for further studies. "Investigational" means that the intervention is being studied. Stereotactic body radiation was developed as imaging and treatment capabilities on radiation treatment machines became more accurate and more precise. Like standard radiation therapy, stereotactic body radiation kills tumor cells by causing small breaks in the DNA of these cells. In this research study, the investigators are looking for the highest dose of the stereotactic radiation that can be given safely either alone, or as a 'boost dose' in combination with standard radiation and chemotherapy. Because stereotactic radiation is so precise, the investigators are testing whether it can be used to increase the dose to the primary tumor without significantly increasing the side effects; the goal is to improve the likelihood of killing the tumor and, in some cases, to complete the course of radiation in a shorter amount of time.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 21
Est. completion date June 2024
Est. primary completion date January 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Participants must meet the following criteria on screening examination to be eligible to participate in the study: - All cohorts: - Participants must have a pathologic cancer diagnosis. - No other active malignancy within the past 2 years, except for non-melanoma skin cancers or carcinoma in situ of the cervix. - Only patients 18 years and older are eligible. There is no upper age limit but the patients must be able to medically tolerate the regimen. Adverse event data are currently unavailable on the use of SBRT for participants < 18 years of age, and thus children are excluded from this study. - Eastern Cooperative Oncology Group (ECOG) performance status =2 (see Appendix A). - Ability to understand and the willingness to sign a written informed consent document - Cohort 1 (reirradiation in patients with head and neck cancers with gross unresectable disease): - History of radiation to the head and neck area (defined as above the clavicles) greater than 6 months previous - Pathologically proven recurrent disease or a second primary (squamous cell carcinoma of the head and neck, nasopharyngeal cancer, salivary gland cancer, or thyroid cancer) within the head and neck region, deemed to be unresectable or resected with gross residual disease remaining (determined by either operative/pathology report or post-surgical imaging) - Participants must have normal organ and marrow function as defined below: - Leukocytes = 3,000/mcL (microliter) - Absolute neutrophil count > ?1,500/mcL (microliter) - Platelets =100,000/mcL (microliter) - Total bilirubin within normal institutional limits - aspartate aminotransferase (AST (SGOT))/alanine aminotransferase (ALT (SGPT)) = 2.5 x institutional upper limit of normal - Creatinine < 2 x upper limit of normal (ULN) or creatinine clearance =45 mL/min/1.73 m2 for subjects with creatinine levels above institutional normal - Cohort 2 (patients with metastatic disease with targetable lesions within the head and neck): - Pathologically proven solid tumor (lymphomas excluded) with evidence of metastatic disease (including nodal disease) - Measurable disease within the head and neck region, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as =10 mm and < 60 mm with neck CT scan. See section 10 for the evaluation of measurable disease. Exclusion Criteria: - Participants who exhibit any of the following conditions at screening will not be eligible for admission into the study. - SBRT target size > 6 cm in maximum diameter (or greater than 100 cc in volume). - Participants may not be receiving any other study agents. - Uncontrolled intercurrent illness including but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. - Pregnant women are excluded from this study because radiotherapy has the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk of adverse events in nursing infants secondary to treatment of the mother with SBRT, breastfeeding should be discontinued if the mother is treated with SBRT. - Individuals with a history of a different malignancy are ineligible except for the following circumstances: if they have been disease-free for at least 2 years and are deemed by the investigator to be at low risk for recurrence of that malignancy; or if diagnosed and treated within the past 2 years for cervical cancer in situ or basal cell or squamous cell carcinoma of the skin. - HIV-positive individuals on combination antiretroviral therapy are ineligible because of the potential for interaction between conventional radiotherapy, SBRT and antiretroviral medications. In addition, these individuals are at increased risk of lethal infections when treated with marrow-suppressive therapy. Appropriate studies will be undertaken in participants receiving combination antiretroviral therapy when indicated. - Patients who are planned to receive the following medications: - Granulocyte stimulating factor (G-CSF) - Bevacizumab - Cyclosporine - Anti-tumor necrosis factor agents - Amifostine

Study Design


Related Conditions & MeSH terms


Intervention

Radiation:
Intensity Modulated Radiation Therapy (IMRT)

Drug:
Cisplatin

Radiation:
Stereotactic Body Radiotherapy (SBRT)


Locations

Country Name City State
United States Dana-Farber Cancer Institute Boston Massachusetts

Sponsors (1)

Lead Sponsor Collaborator
Dana-Farber Cancer Institute

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Maximum tolerated dose of stereotactic body radiotherapy treatment (SBRT) when given as a boost in combination with cisplatin and intensity modulated radiation therapy (IMRT) Cohort 1: patients who have received prior radiation in the head and neck and currently have gross unresectable disease; 1 Year
Primary Maximum tolerated dose of stereotactic body radiotherapy treatment (SBRT) when given for disease metastatic to the head and neck Cohort 2: Patients with metastatic disease with targetable lesions within the head and neck. 1 year
Secondary Number of Participants with Adverse Events Adverse events observed will be summarized in terms of type (organ affected or laboratory determination), severity (by National Cancer Institute, Common Toxicity Criteria for Adverse Effects - CTCAE v4 and nadir or maximum values for the laboratory measures), time of onset (i.e. course number), duration, and reversibility or outcome. Tables will be created to summarize these toxicities and side effects by dose and by course. 1 Year
Secondary Local Control Rate Computed tomography (CT) and Positron emission tomography (PET) will be used to assess disease control within the field receiving radiation. 1 Year
Secondary Regional Control Rate Computed tomography (CT) and Positron emission tomography (PET) will be used to assess disease control within the head and neck region. 1 Year
Secondary Progression Free Survival using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 Progression free survival will be summarized with Kaplan-Meier plots to describe the outcome of patients treated on this protocol. The median progression free survival time will be estimated using standard life table methods. 1 year
Secondary Level of circulating activated T cells as an immune correlate of stereotactic treatment This will evaluate circulating immune cells before and after treatment and gene expression analysis focusing on delineating the immune components and immunologic milieu within the tumor before therapy. 1 Year
Secondary Patient reported physical function before and after treatment This will investigate changes in patient reported quality of life after treatment using the validated University of Washington Quality of Life Questionnaire (UW-QOL v4) composite score for physical function and comparing results obtained before and after treatment. 1 year
Secondary Patient reported social function before and after treatment This will investigate changes in patient reported quality of life after treatment using the validated University of Washington Quality of Life Questionnaire (UW-QOL v4) composite score for social function and comparing results obtained before and after treatment. 1 year
See also
  Status Clinical Trial Phase
Recruiting NCT05980000 - Ramucirumab and Pembrolizumab vs Pembrolizumab Monotherapy in PD-L1 Positive Head and Neck Squamous-Cell Carcinoma Phase 2
Active, not recruiting NCT04514484 - Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV Phase 1
Recruiting NCT03164460 - Stereotactic Body Radiation Therapy or Intensity Modulated Radiation/Proton Therapy in Treating Patients With Recurrent Head and Neck Cancer Phase 2
Active, not recruiting NCT03892720 - Stereotactic Body Radiation Therapy Using HyperArc in Treating Patients With Recurrent Head and Neck Cancer N/A
Completed NCT02467738 - Surgical Resection and Intraoperative Cesium-131 Brachytherapy for Head and Neck Cancer Early Phase 1
Active, not recruiting NCT03049618 - Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475 Phase 2
Active, not recruiting NCT01638533 - Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction Phase 1
Terminated NCT02706691 - BGJ398 in Treating Patients With FGFR Positive Recurrent Head and Neck Cancer Phase 2
Recruiting NCT03727061 - Porfimer Sodium Interstitial Photodynamic Therapy With or Without Standard of Care Chemotherapy in Treating Patients With Locally Advanced or Recurrent Head and Neck Cancer Phase 1
Completed NCT02646319 - Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations Early Phase 1
Completed NCT02318771 - Radiation Therapy and MK-3475 for Patients With Recurrent/Metastatic Head and Neck Cancer, Renal Cell Cancer, Melanoma, and Lung Cancer Phase 1
Completed NCT01727076 - Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-small Cell Lung Cancer, or Squamous Cell Head and Neck Cancer Phase 1
Active, not recruiting NCT00954226 - Phase Ib Study of Erlotinib Prior to Surgery in Patients With Head and Neck Cancer Phase 1
Completed NCT01696955 - Cetuximab With or Without Tivantinib in Treating Patients With Head and Neck Cancer That Is Recurrent, Metastatic, or Cannot Be Removed by Surgery Phase 2
Active, not recruiting NCT02465060 - Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) Phase 2
Completed NCT01846091 - Viral Therapy In Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Cancer or Metastatic Breast Cancer Phase 1